Impact of Hereditary vs Wild-Type ATTR-CM – Compliance Alert

Lower Risk

This Disease Education video is within acceptable compliance thresholds.

Analysis of this 201s Disease Education video identified 2 enforcement patterns, primarily Fair Balance. Patterns span Efficacy, Fair Balance — “Comparative Claims” identified at 7.3s, previously cited in NEXLIZET, COBENFY. Benefit-to-risk presentation ratio is 7.8:1.

Video Timeline

Risk disclosure: 89.1s – 111.8s (22.7s of 200.7s total — 11.3% of ad)

Risk Window

0s50s100s151s201s

No visual distractions detected

Risk Window?

Patterns Detected (2)

Each pattern below is a known FDA enforcement concern, identified by matching this ad against 14 violation types from 34 FDA warning letters

Pattern	Dimension	Score	Evidence	CFR
Comparative Claims Claims suggesting superiority without adequate supporting data	Efficacy	91	1 clip	21 CFR 202.1(e)(5)	▶
FDA Concern: Advertisements cannot be false or misleading in any particular Previously cited: NEXLIZET, COBENFY
Benefit vs. Risk Time Imbalance Significantly more time spent on benefits than on risks	Fair Balance	78	1 metric	21 CFR 202.1(e)(3)(iii)	▶
FDA Concern: Risk and benefit information must be presented with equal prominence Previously cited: FABHALTA, Vyvgart Hytrulo (x2), Wegovy, Vonjo Benefit:Risk Ratio: 7.83:1

Compliance Alert: Impact of Hereditary vs Wild-Type ATTR-CM

Recommendations